Erratum
Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications. 2010;2:225–236.On page 233, left-hand column, se...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4661cd22815e45a38a7a073d3b1ff685 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4661cd22815e45a38a7a073d3b1ff685 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4661cd22815e45a38a7a073d3b1ff6852021-12-02T02:08:52ZErratum1179-1438https://doaj.org/article/4661cd22815e45a38a7a073d3b1ff6852012-03-01T00:00:00Zhttp://www.dovepress.com/erratum-neuronal-potassium-channel-a9568https://doaj.org/toc/1179-1438Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications. 2010;2:225–236.On page 233, left-hand column, second paragraph, line 17 forward, it says:“The most common reasons for discontinuation were dizziness, confusion, somnolence, and asthenia, with the highest proportion of withdrawals in patients receiving retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine was used at 1200 mg/kg, urinary or renal disorders were observed in 12% of patients.”In this passage, both instances of “retigabine 1200 mg/kg” should be “retigabine 1200 mg/day.”Read original articleBarrese VMiceli FSoldovieri MVAmbrosino PIannotti FACilio MRTaglialatela MDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2012, Iss default, Pp 23-24 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Therapeutics. Pharmacology RM1-950 Barrese V Miceli F Soldovieri MV Ambrosino P Iannotti FA Cilio MR Taglialatela M Erratum |
| description |
Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications. 2010;2:225–236.On page 233, left-hand column, second paragraph, line 17 forward, it says:“The most common reasons for discontinuation were dizziness, confusion, somnolence, and asthenia, with the highest proportion of withdrawals in patients receiving retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine was used at 1200 mg/kg, urinary or renal disorders were observed in 12% of patients.”In this passage, both instances of “retigabine 1200 mg/kg” should be “retigabine 1200 mg/day.”Read original article |
| format |
article |
| author |
Barrese V Miceli F Soldovieri MV Ambrosino P Iannotti FA Cilio MR Taglialatela M |
| author_facet |
Barrese V Miceli F Soldovieri MV Ambrosino P Iannotti FA Cilio MR Taglialatela M |
| author_sort |
Barrese V |
| title |
Erratum |
| title_short |
Erratum |
| title_full |
Erratum |
| title_fullStr |
Erratum |
| title_full_unstemmed |
Erratum |
| title_sort |
erratum |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/4661cd22815e45a38a7a073d3b1ff685 |
| work_keys_str_mv |
AT barresev erratum AT micelif erratum AT soldovierimv erratum AT ambrosinop erratum AT iannottifa erratum AT ciliomr erratum AT taglialatelam erratum |
| _version_ |
1718402645550432256 |